bluebird bio (BLUE) News Today $0.30 0.00 (0.00%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Bluebird Bio: Hold Rating Amid Positive Patient Starts and Financing ChallengesNovember 19 at 2:24 PM | markets.businessinsider.combluebird bio (NASDAQ:BLUE) Now Covered by StockNews.comStockNews.com started coverage on shares of bluebird bio in a research report on Monday. They set a "sell" rating on the stock.November 18 at 3:24 AM | marketbeat.comBarclays Cuts bluebird bio (NASDAQ:BLUE) Price Target to $2.00November 18 at 2:10 AM | americanbankingnews.comB of A Securities Downgrades bluebird bio (BLUE)November 17, 2024 | msn.combluebird bio (NASDAQ:BLUE) Stock Rating Lowered by Bank of AmericaNovember 17, 2024 | americanbankingnews.combluebird bio, Inc. (NASDAQ:BLUE) Q3 2024 Earnings Call TranscriptNovember 15, 2024 | msn.combluebird bio Inc (BLUE) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges and ...November 15, 2024 | finance.yahoo.combluebird bio extends selloff as BofA and J.P. Morgan cut after Q3 resultsNovember 15, 2024 | msn.comBluebird Bio price target lowered to $2 from $4 at BarclaysNovember 15, 2024 | markets.businessinsider.comBluebird Bio downgraded to Neutral at BofA on slower expected Lyfgenia rampNovember 15, 2024 | markets.businessinsider.comJP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding OptionsNovember 15, 2024 | benzinga.comRoyal Bank of Canada Reaffirms "Sector Perform" Rating for bluebird bio (NASDAQ:BLUE)Royal Bank of Canada reiterated a "sector perform" rating and issued a $4.00 target price on shares of bluebird bio in a research note on Friday.November 15, 2024 | marketbeat.combluebird bio downgraded by Bank of America, shares tumbleNovember 15, 2024 | proactiveinvestors.combluebird bio (NASDAQ:BLUE) Price Target Lowered to $2.00 at BarclaysBarclays lowered their target price on shares of bluebird bio from $4.00 to $2.00 and set an "overweight" rating for the company in a research note on Friday.November 15, 2024 | marketbeat.comJPMorgan Chase & Co. Downgrades bluebird bio (NASDAQ:BLUE) to UnderweightJPMorgan Chase & Co. downgraded shares of bluebird bio from a "neutral" rating to an "underweight" rating in a research note on Friday.November 15, 2024 | marketbeat.combluebird bio (NASDAQ:BLUE) Downgraded to "Neutral" Rating by Bank of AmericaBank of America cut shares of bluebird bio from a "buy" rating to a "neutral" rating and dropped their price objective for the company from $3.00 to $0.50 in a research note on Friday.November 15, 2024 | marketbeat.comExploring bluebird bio's Earnings ExpectationsNovember 13, 2024 | benzinga.comStockNews.com Initiates Coverage on bluebird bio (NASDAQ:BLUE)StockNews.com assumed coverage on bluebird bio in a report on Sunday. They set a "sell" rating on the stock.November 10, 2024 | marketbeat.comBluebird Bio’s Key Decisions and Shareholder Engagement in 2024November 7, 2024 | markets.businessinsider.combluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results CallNovember 7, 2024 | finance.yahoo.combluebird bio (NASDAQ:BLUE) Now Covered by Analysts at StockNews.comStockNews.com assumed coverage on shares of bluebird bio in a report on Saturday. They issued a "sell" rating for the company.November 2, 2024 | marketbeat.combluebird bio (BLUE): Promising Gene Editing Stock with FDA-Approved TherapiesOctober 31, 2024 | msn.combluebird bio, Inc. (NASDAQ:BLUE) Receives Consensus Recommendation of "Hold" from AnalystsShares of bluebird bio, Inc. (NASDAQ:BLUE - Get Free Report) have received an average recommendation of "Hold" from the twelve brokerages that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, seven have issued a hold rating aOctober 29, 2024 | marketbeat.combluebird bio (NASDAQ:BLUE) Research Coverage Started at StockNews.comStockNews.com started coverage on shares of bluebird bio in a report on Friday. They issued a "sell" rating on the stock.October 25, 2024 | marketbeat.comLife Without Sickle Cell Beckons Boy Who Completed Gene TherapyOctober 22, 2024 | nytimes.comMillennium Management LLC Sells 1,092,888 Shares of bluebird bio, Inc. (NASDAQ:BLUE)Millennium Management LLC reduced its position in bluebird bio, Inc. (NASDAQ:BLUE - Free Report) by 17.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,146,653 shares of the biotechnology company's stocOctober 12, 2024 | marketbeat.comLentiviral Gene Therapy Beneficial for Early Cerebral AdrenoleukodystrophyOctober 11, 2024 | msn.comMaintaining Hold on Bluebird Bio Amid Skysona Safety Concerns and Financial ConstraintsOctober 11, 2024 | markets.businessinsider.com7 children given bluebird's Skysona developed blood cancer: studyOctober 11, 2024 | msn.comBluebird bio’s Skysona led to seven cases of blood cancer in gene therapy trialsOctober 11, 2024 | msn.comBluebird Bio (BLUE) Stock Dips Amid Market VolatilityOctober 8, 2024 | gurufocus.comRenaissance Technologies LLC Sells 1,396,196 Shares of bluebird bio, Inc. (NASDAQ:BLUE)Renaissance Technologies LLC cut its stake in shares of bluebird bio, Inc. (NASDAQ:BLUE - Free Report) by 63.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 791,504 shares of the biotechnology company'sOctober 8, 2024 | marketbeat.combluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 4, 2024 | businesswire.combluebird bio, Inc. (NASDAQ:BLUE) Given Average Rating of "Hold" by BrokeragesShares of bluebird bio, Inc. (NASDAQ:BLUE - Get Free Report) have received an average recommendation of "Hold" from the twelve ratings firms that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendatOctober 4, 2024 | marketbeat.comBluebird Bio (BLUE) Stock Surges 5.04% Amid Market MovementsOctober 2, 2024 | gurufocus.comBluebird Bio’s Restructuring Efforts and Financial Outlook: A Cautious Hold RatingSeptember 28, 2024 | markets.businessinsider.comLeerink Partnrs Weighs in on bluebird bio, Inc.'s Q2 2024 Earnings (NASDAQ:BLUE)bluebird bio, Inc. (NASDAQ:BLUE - Free Report) - Equities research analysts at Leerink Partnrs upped their Q2 2024 earnings estimates for bluebird bio in a report issued on Tuesday, September 24th. Leerink Partnrs analyst M. Foroohar now expects that the biotechnology company will post earnings pSeptember 27, 2024 | marketbeat.comLeerink Partnrs Comments on bluebird bio, Inc.'s Q4 2025 Earnings (NASDAQ:BLUE)bluebird bio, Inc. (NASDAQ:BLUE - Free Report) - Stock analysts at Leerink Partnrs issued their Q4 2025 EPS estimates for bluebird bio in a research note issued to investors on Tuesday, September 24th. Leerink Partnrs analyst M. Foroohar forecasts that the biotechnology company will earn ($0.04)September 26, 2024 | marketbeat.comMaintaining Hold on Bluebird Bio: Balancing LYFGENIA’s Promise Against Financial and Operational HurdlesSeptember 25, 2024 | markets.businessinsider.combluebird bio (NASDAQ:BLUE) PT Lowered to $2.00Wells Fargo & Company decreased their price target on shares of bluebird bio from $3.00 to $2.00 and set an "equal weight" rating on the stock in a research note on Wednesday.September 25, 2024 | marketbeat.combluebird bio to cut workforce by about 25%September 24, 2024 | msn.comBluebird bio to cut 25% of workforce as part of restructuringSeptember 24, 2024 | reuters.com1 growth stock that could skyrocket over the next 10 yearsSeptember 19, 2024 | msn.combluebird bio, Inc. (NASDAQ:BLUE) to Post FY2024 Earnings of ($1.31) Per Share, Cantor Fitzgerald Forecastsbluebird bio, Inc. (NASDAQ:BLUE - Free Report) - Research analysts at Cantor Fitzgerald boosted their FY2024 earnings per share estimates for shares of bluebird bio in a report released on Monday, September 16th. Cantor Fitzgerald analyst E. Schmidt now expects that the biotechnology company willSeptember 18, 2024 | marketbeat.com2 Penny Stocks To Buy With Just $250September 16, 2024 | 247wallst.combluebird bio (NASDAQ:BLUE) Given "Neutral" Rating at Cantor FitzgeraldCantor Fitzgerald restated a "neutral" rating on shares of bluebird bio in a report on Monday.September 16, 2024 | marketbeat.comShort Interest in bluebird bio, Inc. (NASDAQ:BLUE) Grows By 20.0%bluebird bio, Inc. (NASDAQ:BLUE - Get Free Report) saw a large growth in short interest during the month of August. As of August 31st, there was short interest totalling 49,370,000 shares, a growth of 20.0% from the August 15th total of 41,140,000 shares. Based on an average daily trading volume, of 7,240,000 shares, the days-to-cover ratio is currently 6.8 days.September 15, 2024 | marketbeat.combluebird bio, Inc. (NASDAQ:BLUE) Given Average Rating of "Hold" by AnalystsShares of bluebird bio, Inc. (NASDAQ:BLUE - Get Free Report) have been given an average rating of "Hold" by the twelve research firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, seven have issued a hold rating aSeptember 9, 2024 | marketbeat.combluebird bio (NASDAQ:BLUE) Stock Price Crosses Below 200-Day Moving Average of $1.06bluebird bio (NASDAQ:BLUE) Shares Cross Below 200-Day Moving Average of $1.06September 7, 2024 | marketbeat.combluebird bio, Inc. (NASDAQ:BLUE) Sees Significant Increase in Short Interestbluebird bio, Inc. (NASDAQ:BLUE - Get Free Report) was the target of a significant growth in short interest during the month of August. As of August 15th, there was short interest totalling 41,140,000 shares, a growth of 32.2% from the July 31st total of 31,130,000 shares. Based on an average trading volume of 6,720,000 shares, the short-interest ratio is currently 6.1 days.August 30, 2024 | marketbeat.com Get bluebird bio News Delivered to You Automatically Sign up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners… Claim your FREE 2024 Gold Guide BLUE Media Mentions By Week BLUE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BLUE News Sentiment▼-0.070.45▲Average Medical News Sentiment BLUE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BLUE Articles This Week▼226▲BLUE Articles Average Week Get bluebird bio News Delivered to You Automatically Sign up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AlloVir News Today Tevogen Bio News Today TScan Therapeutics News Today Sutro Biopharma News Today Molecular Partners News Today SOPHiA GENETICS News Today Genfit News Today Inhibrx News Today Zura Bio News Today Editas Medicine News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BLUE) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding bluebird bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share bluebird bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BLUE Stock Alerts